United States Securities and Exchange Commission · EDGAR Accession 0001822782-26-000003

Form C-AR

Annual Report — Regulation Crowdfunding
Issuer CIK 1822782
Period 2025-12-31

Deverra Therapeutics, Inc.

CorporationDEIncorporated 2020Seattle, WAdeverratx.com
B

Financial Condition

two fiscal years, as filed
Revenue −82% YoYBurn decreasingDebt / assets 15%1 employee
Line itemMost recent FYPrior FYΔ
Revenue696,7273,879,188▼ 82%
Cost of goods sold696,7273,879,188▼ 82%
Net income(1,523,035)(3,718,063)▲ burn
Total assets10,077,33411,309,047▼ 11%
Cash & equivalents1,612115
Accounts receivable00
Short-term debt1,435,0001,690,073▼ 15%
Long-term debt102,9170
Taxes paid29,69472,893▼ 59%

Figures in USD as reported by the issuer.